Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapyMelody Smith, Marco Ruella, Elizabeth Halton et al.|Nature Medicine|2022Cited by 308
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapyGuido Ghilardi, Marco Ruella, Joseph A. Fraietta et al.|Nature Medicine|2024Cited by 254
Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against CancerYong Gu Lee, Marco Ruella, Puneeth Guruprasad et al.|Cancer Discovery|2022Cited by 98
Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomasGuido Ghilardi, Stephen J. Schuster, Elise A. Chong et al.|Annals of Oncology|2022Cited by 95
The BTLA–HVEM axis restricts CAR T cell efficacy in cancerPuneeth Guruprasad, Marco Ruella, Alberto Carturan et al.|Nature Immunology|2024Cited by 41